Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: A prospective randomized clinical study

Giammaria Fiorentini, D. B. Poddie, M. Cantore, S. Rossi, S. Tumolo, P. Dentico, P. Bernardeschi, S. Guadagni, G. Rossi, V. M. Valori, M. De Simone

Research output: Contribution to journalArticlepeer-review

Abstract

A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%. The median survival was 17 vs 11 months and the responses were 65% vs 33%. Toxicity was colangitis in 50% of patients considered. The extrahepatic progression was similar in the two groups (7/20 vs 8/22).

Original languageEnglish
Pages (from-to)51-54
Number of pages4
JournalJournal of Chemotherapy
Volume16
Issue numberSUPPL. 5
Publication statusPublished - Nov 2004

Keywords

  • Chemofiltration
  • Intra-arterial chemotherapy
  • Liver metastases

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: A prospective randomized clinical study'. Together they form a unique fingerprint.

Cite this